DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
s••••••••• I••
Pharmaceuticalsgroup grade Aoff every schedule since Jun 30, 2025sponsor unattributed
Nothing material in the last 200 days. No dated change on record yet.
Principal held
unknown
sum of BDC pieces, a lower bound
Fair value
$200,000
n/a on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
2
2 on the latest quarter
Facilities
2
2 equity pieces beside them
Next maturity
unstated
no dated debt inside 24 months
On the tape since
Sep 30, 2022
latest Jun 30, 2025
Events
3
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2025, folded to one row per lender
Every BDC piece · 2 positions across 2 lenderslargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| O•••••• S•••••••• L•••••• C••• | warrants equity W••••••• | Not disclosed | $81,000 46c | |
| O•••••• S•••••••• C••••• F••• | warrants equity W••••••• | Not disclosed | $119,000 46c |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2025
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Jun 30, 2024 | at least $12.9M | 101c | S+875 bp | Oct 13, 2027 | 2 |
| first lien delayed draw term loan first lien exited Dec 31, 2022 | at least $0 | n/a | S+875 bp | unstated | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2 | $0 | $0 | n/a | 0 |
| Mar 31, 2025 | 2 | $0 | $0 | n/a | 0 |
| Dec 31, 2024 | 2 | $0 | $0 | n/a | 0 |
| Sep 30, 2024 | 2 | $0 | $0 | n/a | 0 |
All 12 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2024 | 2 | $12.9M | $12.5M | 101c | 0 |
| Mar 31, 2024 | 2 | $12.9M | $12.5M | 101c | 0 |
| Dec 31, 2023 | 2 | $12.9M | $12.4M | 101c | 0 |
| Sep 30, 2023 | 2 | $12.9M | $12.3M | 100c | 0 |
| Jun 30, 2023 | 2 | $12.9M | $12.4M | 101c | 0 |
| Mar 31, 2023 | 2 | $12.9M | $12.4M | 101c | 0 |
| Dec 31, 2022 | 1 | $5.2M | $5.0M | 100c | 0 |
| Sep 30, 2022 | 2 | $0 | $0 | n/a | 0 |
What changed
- Facility left every BDC scheduleJun 30, 2024
- New lender joined a facilityMar 31, 2023
- Facility left every BDC scheduleDec 31, 2022
- New borrower on a BDC scheduleSep 30, 2022
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- SCPHARMACEUTICALSderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 2 BDCsderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it